Payment overview · 2025
General Payments
$617.18
33 reported records · 11 companies
Healthcare provider profile · identity verified
Lee A Colyar, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · JOHNSON CITY, TN · NPI 1386626166
Verified facts
What the public records show
CMS Open Payments records show Lee A Colyar, M.D. received $617.18 in general payments during 2025 across 33 reported records.
Novo Nordisk Inc accounted for 22.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $139.26 | 22.6% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $86.55 | 14.0% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $62.51 | 10.1% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $56.60 | 9.2% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $44.66 | 7.2% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.54 | 7.2% | 3 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $41.40 | 6.7% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $39.32 | 6.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.80 | 5.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.34 | 5.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.20 | 5.4% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $617.18 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $74.57 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $71.52 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $62.51 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $62.51 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $56.60 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $47.41 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $44.73 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $44.66 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $44.54 | 3 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $41.40 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $39.32 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $38.67 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $34.80 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $34.34 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $34.34 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $34.34 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $33.20 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 35 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
35 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
58 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 343 | 102 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 343 | 94 |
| Levothyroxine Sodium | Levothyroxine Sodium | 327 | 78 |
| Atorvastatin Calcium | Atorvastatin Calcium | 319 | 92 |
| Omeprazole | Omeprazole | 317 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 303 | 85 |
| Losartan Potassium | Losartan Potassium | 272 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 246 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 223 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 221 | 62 |
| Simvastatin | Simvastatin | 181 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 175 | 45 |
| Gabapentin | Gabapentin | 171 | 42 |
| Metformin Hcl Er | Metformin Hcl | 168 | 49 |
| Furosemide | Furosemide | 147 | 39 |
| Alprazolam | Alprazolam | 137 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 132 | 41 |
| Celecoxib | Celecoxib | 131 | 46 |
| Allopurinol | Allopurinol | 125 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 125 | 30 |
| Meloxicam | Meloxicam | 119 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 108 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 107 | 21 |
| Pregabalin | Pregabalin | 105 | 21 |
| Finasteride | Finasteride | 103 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 99 | 32 |
| Potassium Chloride | Potassium Chloride | 96 | 27 |
| Montelukast Sodium | Montelukast Sodium | 90 | 18 |
| Metformin Hcl | Metformin Hcl | 89 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 20 |
| Sertraline Hcl | Sertraline Hcl | 73 | 25 |
| Clonazepam | Clonazepam | 69 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 20 |
| Carvedilol | Carvedilol | 66 | 17 |
| Terazosin Hcl | Terazosin Hcl | 64 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | suppressed |
| Spironolactone | Spironolactone | 61 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 19 |
| Tramadol Hcl | Tramadol Hcl | 59 | 13 |
| Eliquis | Apixaban | 58 | 15 |
| Trulicity | Dulaglutide | 57 | suppressed |
| Famotidine | Famotidine | 55 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 15 |
| Glimepiride | Glimepiride | 51 | 15 |
| Nifedipine Er | Nifedipine | 49 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 46 | 24 |
| Clonidine Hcl | Clonidine Hcl | 46 | 14 |
| Levetiracetam | Levetiracetam | 45 | suppressed |
| Mirtazapine | Mirtazapine | 45 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 45 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 43 | 12 |
| Glipizide Er | Glipizide | 42 | 12 |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 41 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | 13 |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Lamotrigine | Lamotrigine | 40 | suppressed |
| Lorazepam | Lorazepam | 39 | suppressed |
| Prednisone | Prednisone | 39 | 15 |
| Trazodone Hcl | Trazodone Hcl | 39 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 36 | 11 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 35 | 35 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | 12 |
| Irbesartan | Irbesartan | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 26 | 22 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 25 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Metolazone | Metolazone | 21 | suppressed |
| Nabumetone | Nabumetone | 21 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 11 |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 12 |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Sprintec | Norgestimate-Ethinyl Estradiol | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 12 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Fycompa | Perampanel | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Rufinamide | Rufinamide | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $617.18 · 33 records | Novo Nordisk Inc | ABRYSVO, COMIRNATY, EVENITY, GVOKE HYPOPEN, Heplisav-B, MOUNJARO, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error